MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

Search

Compugen Ltd

Geschlossen

1.53 -0.65

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

1.5

Max

1.63

Schlüsselkennzahlen

By Trading Economics

Einkommen

-1.1M

-7.2M

Verkäufe

813K

2.3M

KGV

Branchendurchschnitt

60.333

39.857

Gewinnspanne

-314.405

Angestellte

74

EBITDA

-912K

-8.4M

Empfehlungen

By TipRanks

Empfehlungen

Starkes Kaufsignal

12-Monats-Prognose

+343.04% upside

Dividenden

By Dow Jones

Nächstes Ergebnis

5. Aug. 2025

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

-536M

151M

Vorheriger Eröffnungskurs

2.18

Vorheriger Schlusskurs

1.53

Technischer Score

By Trading Central

Vertrauen

Very Strong Bearish Evidence

Compugen Ltd Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

18. Juli 2025, 21:01 UTC

Ergebnisse

Charles Schwab Profit Jumps on Tariff Trading Surge -- 2nd Update

18. Juli 2025, 20:50 UTC

Market Talk
Ergebnisse

Tech, Media & Telecom Roundup: Market Talk

18. Juli 2025, 20:50 UTC

Market Talk
Ergebnisse

Auto & Transport Roundup: Market Talk

18. Juli 2025, 20:50 UTC

Market Talk
Ergebnisse

Basic Materials Roundup: Market Talk

18. Juli 2025, 20:46 UTC

Ergebnisse

Strong Earnings Fuel Stock-Market Records This Week -- WSJ

18. Juli 2025, 20:39 UTC

Akquisitionen, Fusionen, Übernahmen

Union Pacific Considering a Norfolk Southern Buyout, Report Says. Here's What Will Matter. -- Barrons.com

18. Juli 2025, 20:36 UTC

Ergebnisse

3M Gives Investors a 'Beat and Raise.' The Stock Is Rising. -- Barrons.com

18. Juli 2025, 20:16 UTC

Akquisitionen, Fusionen, Übernahmen

Chevron-Hess Deal Close Is Good News for Wall Street's Takeover Arbitragers -- Barrons.com

18. Juli 2025, 20:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

18. Juli 2025, 20:02 UTC

Market Talk

Gold Higher to Close Out Week -- Market Talk

18. Juli 2025, 19:14 UTC

Market Talk

U.S. Natural Gas Futures Post Weekly Gains -- Market Talk

18. Juli 2025, 19:06 UTC

Market Talk

Oil Futures Snap Two-Week Winning Streak -- Market Talk

18. Juli 2025, 18:24 UTC

Ergebnisse

These Stocks Are Moving the Most Today: Netflix, Sarepta, Amex, Norfolk Southern, Interactive Brokers, Talen, Schwab, and More -- Barrons.com

18. Juli 2025, 18:19 UTC

Ergebnisse

American Express Shares Drop as Earnings Beat, Record Revenue Fail to Impress -- Barrons.com

18. Juli 2025, 18:11 UTC

Akquisitionen, Fusionen, Übernahmen

Oil CEOs Get Their Revenge on Biden's Antitrust Enforcers -- WSJ

18. Juli 2025, 18:11 UTC

Ergebnisse

Netflix Earnings Show That YouTube Is the Streamer to Fear -- Barrons.com

18. Juli 2025, 17:35 UTC

Market Talk

U.S. Oil Rig Count Falls by 2 to 422 -- Market Talk

18. Juli 2025, 16:29 UTC

Market Talk

Crude Rally on EU's Russia Sanctions Peters Out -- Market Talk

18. Juli 2025, 16:28 UTC

Akquisitionen, Fusionen, Übernahmen

Union Pacific Considering a Norfolk Southern Buyout, Report Says. Here's What Will Matter. -- Barrons.com

18. Juli 2025, 16:22 UTC

Ergebnisse

These Stocks Are Moving the Most Today: Netflix, Amex, Norfolk Southern, Interactive Brokers, Talen, Schwab, Sarepta, and More -- Barrons.com

18. Juli 2025, 16:20 UTC

Market Talk
Ergebnisse

Financial Services Roundup: Market Talk

18. Juli 2025, 16:20 UTC

Market Talk
Ergebnisse

Tech, Media & Telecom Roundup: Market Talk

18. Juli 2025, 16:20 UTC

Market Talk
Ergebnisse

Auto & Transport Roundup: Market Talk

18. Juli 2025, 16:20 UTC

Market Talk
Akquisitionen, Fusionen, Übernahmen

Energy & Utilities Roundup: Market Talk

18. Juli 2025, 16:20 UTC

Market Talk
Ergebnisse

Basic Materials Roundup: Market Talk

18. Juli 2025, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

18. Juli 2025, 16:04 UTC

Ergebnisse

Charles Schwab Profit Jumps on Tariff Trading Surge -- Update

18. Juli 2025, 15:58 UTC

Market Talk

Global Equities Roundup: Market Talk

18. Juli 2025, 15:58 UTC

Market Talk

Aluminum Gains on U.S. Dollar Weakness, Scrap Imports -- Market Talk

18. Juli 2025, 15:47 UTC

Market Talk
Ergebnisse

Netflix Shifting Focus to Engagement with New Content -- Market Talk

Peer-Vergleich

Kursveränderung

Compugen Ltd Prognose

Kursziel

By TipRanks

343.04% Vorteil

12-Monats-Prognose

Durchschnitt 7 USD  343.04%

Hoch 10 USD

Tief 4 USD

Basierend auf 3 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Compugen Ltd – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

3 ratings

3

Buy

0

Halten

0

Sell

Technischer Score

By Trading Central

1.25 / 1.48Unterstützung & Widerstand

Kurzfristig

Very Strong Bearish Evidence

Mittelfristig

Very Strong Bearish Evidence

Langfristig

Weak Bearish Evidence

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Compugen Ltd

Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I monotherapy clinical study in patients with advanced malignancies through sequential dose escalations; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase II clinical study in patients with advanced or metastatic non-small cell lung cancer. Its therapeutic pipeline also includes early-stage immuno-oncology programs focused to address various mechanisms of immune resistance; and COM503, high affinity antibody, which blocks the interaction between IL-18 binding protein and IL-18. The company has collaboration agreement with Bayer Pharma AG for the research, development, and commercialization of antibody-based therapeutics against the company's immune checkpoint regulators; Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors; and Johns Hopkins School of Medicine to evaluate novel T cell and myeloid checkpoint targets. It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products; and research collaboration with Johns Hopkins University for myeloid. Compugen Ltd. was incorporated in 1993 and is headquartered in Holon, Israel.